GELASPAN

This brand name is authorized in Ecuador, Estonia, France, Ireland, Lithuania, Malta, Netherlands, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug GELASPAN contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 2G86QN327L - GELATIN, UNSPECIFIED
 

Gelatin is a colloidal plasma substitute. When used in the treatment of hypovolaemia gelatin produces significant increases in blood volume, cardiac output, stroke volume, blood pressure, urinary output and oxygen delivery. Gelatin promotes osmotic diuresis, thereby helping to protect the kidneys from the adverse effects of hypovolaemia.

 
Read more about Gelatin
2
UNII 451W47IQ8X - SODIUM CHLORIDE
 

Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue.

 
Read more about Sodium chloride
3
UNII 4550K0SC9B - SODIUM ACETATE
 
Read more about Sodium acetate
4
UNII 660YQ98I10 - POTASSIUM CHLORIDE
 

Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism.

 
Read more about Potassium chloride
5
UNII M4I0D6VV5M - CALCIUM CHLORIDE
 

Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat.

 
Read more about Calcium chloride
6
UNII 02F3473H9O - MAGNESIUM CHLORIDE
 
Read more about Magnesium chloride

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
B05AA06 Gelatin agents B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05A Blood and related products → B05AA Blood substitutes and plasma protein fractions
Discover more medicines within B05AA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 974-MEE-0515
EE Ravimiamet 1722158, 1722169
ES Centro de información online de medicamentos de la AEMPS 76222
FR Base de données publique des médicaments 69083660
GB Medicines & Healthcare Products Regulatory Agency 212914, 239837
LT Valstybinė vaistų kontrolės tarnyba 1053843, 1053844
MT Medicines Authority MA223/01501
NL Z-Index G-Standaard, PRK 38040
PL Rejestru Produktów Leczniczych 100254217
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W57829001, W57829002
SG Health Sciences Authority 15336P

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.